Sintilimab Combined With Lenvatinib Versus HAIC for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, Two-arm, randomized，phase II clinical study of Sintilimab Combined With Lenvatinib Versus HAIC for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
Resectable Hepatocellular Carcinoma
DRUG: Sintilimab and Lenvatinib|DRUG: HAIC-FOLFOX
1-year DFS%, 1-year disease-free survival rate, 12month
ORR, objective response rate, 3 months|Percentage of MVI, Microvascular invasion, 4 months|Percentage of pCR, pathological complete response, 4 months|2-year DFS%, 2-year disease-free survival rate, 24 months
This is a prospective, Two-arm, randomized，phase II clinical study of Sintilimab Combined With Lenvatinib Versus HAIC for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.